Mostrar el registro sencillo del ítem

dc.contributor.authorJabalera Ruz, Ylenia María 
dc.contributor.authorSola Leyva, Alberto 
dc.contributor.authorCarrasco Jiménez, María Paz 
dc.contributor.authorIglesias Salto, Guillermo Ramón 
dc.contributor.authorJiménez López, Concepción 
dc.date.accessioned2021-05-10T12:05:23Z
dc.date.available2021-05-10T12:05:23Z
dc.date.issued2021
dc.identifier.citationJabalera, Y.; Sola-Leyva, A.; Carrasco-Jiménez, M.P.; Iglesias, G.R.; Jimenez-Lopez, C. Synergistic Photothermal-Chemotherapy Based on the Use of Biomimetic Magnetic Nanoparticles. Pharmaceutics 2021, 13, 625. https://doi.org/10.3390/ pharmaceutics13050625es_ES
dc.identifier.urihttp://hdl.handle.net/10481/68438
dc.description.abstractMamC-mediated biomimetic magnetic nanoparticles (BMNPs) have emerged as one of the most promising nanomaterials due to their magnetic features (superparamagnetic character and large magnetic moment per particle), their novel surface properties determined by MamC, their biocompatibility and their ability as magnetic hyperthermia agents. However, the current clinical application of magnetic hyperthermia is limited due to the fact that, in order to be able to reach an effective temperature at the target site, relatively high nanoparticle concentration, as well as high magnetic field strength and/or AC frequency are needed. In the present study, the potential of BMNPs to increase the temperature upon irradiation of a laser beam in the near infrared, at a wavelength at which tissues become partially transparent, is explored. Moreover, our results also demonstrate the synergy between photothermia and chemotherapy in terms of drug release and cytotoxicity, by using BMNPs functionalized with doxorubicin, and the effectiveness of this combination therapy against tumor cells in in vitro experiments. Therefore, the findings of the present study open the possibility of a novel, alternative approach to fight localized tumors.es_ES
dc.description.sponsorshipMinisterio de Economía y Competitividad (CGL2016- 76723 and PID2019-109294RB-100 projects)es_ES
dc.description.sponsorshipRamón y Cajal program (RYC-2014-16901)es_ES
dc.description.sponsorshipJunta de Andalucía. Programa Operativo FEDER 2014–2020. (A1-FQM-341-UGR18, C-FQM-497-UGR18, A-BIO376-UGR18).es_ES
dc.description.sponsorshipAndalusian regional government (CTS-236)es_ES
dc.description.sponsorshipFormación de Doctores 2018 grant (ref. PRE2018-085440) from the Ministerio de Ciencia, Innovación y Universidades (Spain)es_ES
dc.description.sponsorshipUnidad Cientifica de Excelencia UCE-PP2016-05es_ES
dc.description.sponsorshipInstituto de Biotecnología of the University of Granadaes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectBiomimetic magnetic nanoparticleses_ES
dc.subjectCombined tumor therapyes_ES
dc.subjectDoxorubicines_ES
dc.subjectHepG2 cancer cell linees_ES
dc.subjectMamCes_ES
dc.subjectMagnetite nanoparticleses_ES
dc.subjectPhotothermiaes_ES
dc.titleSynergistic Photothermal-Chemotherapy Based on the Use of Biomimetic Magnetic Nanoparticleses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.3390/pharmaceutics13050625


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España